Mikä on BST2 geeni ja proteiini? (Recommended name: Bone marrow stromal antigen 2 ( Kr. 19p13.11)

 https://www.genecards.org/cgi-bin/carddisp.pl?gene=BST2&keywords=BST2

Aliases for BST2 Gene

• GeneCards Symbol: BST2 ²
• Bone Marrow Stromal Cell Antigen 2 ^{2 3 5}
• Tetherin ^{2 3 4 5}
• BST-2 ^{2 3 4 5}
• HM1.24 ^{2 3 5}
• CD317 ^{2 3 5}

• Bone Marrow Stromal Antigen 2 ^{3 4}
• Antiviral Factor Tetherin ^{2 3}
• HM1.24 Antigen ^{3 4}
• CD317 Antigen ⁴
• NPC-A-7 ³

External Ids for BST2 Gene

NCBI Gene Summary for BST2 Gene

• Bone marrow stromal cells are involved in the growth and development of B-cells. The specific function of the protein encoded by the bone marrow stromal cell antigen 2 is undetermined; however, this protein may play a role in pre-B-cell growth and in rheumatoid arthritis. [provided by RefSeq, Jul 2008]

GeneCards Summary for BST2 Gene

BST2 (Bone Marrow Stromal Cell Antigen 2) is a Protein Coding gene. Diseases associated with BST2 include Stomatitis and Colorado Tick Fever. Among its related pathways are Infectious disease and SARS-CoV-1-host interactions. Gene Ontology (GO) annotations related to this gene include RNA binding and obsolete signal transducer activity.

UniProtKB/Swiss-Prot Summary for BST2 Gene

IFN-induced antiviral host restriction factor which efficiently blocks the release of diverse mammalian enveloped viruses by directly tethering nascent virions to the membranes of infected cells. Acts as a direct physical tether, holding virions to the cell membrane and linking virions to each other. The tethered virions can be internalized by endocytosis and subsequently degraded or they can remain on the cell surface. In either case, their spread as cell-free virions is restricted (PubMed:18200009, 18342597, 19036818, 19879838, 20019814, 20399176, 20419159, 20940320, 21529378, 22520941, 37922253). Its target viruses belong to diverse families, including retroviridae: human immunodeficiency virus type 1 (HIV-1), human immunodeficiency virus type 2 (HIV-2), simian immunodeficiency viruses (SIVs), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), prototype foamy virus (PFV), Mason-Pfizer monkey virus (MPMV), human T-cell leukemia virus type 1 (HTLV-1), Rous sarcoma virus (RSV) and murine leukemia virus (MLV), flavivirideae: hepatitis C virus (HCV), filoviridae: ebola virus (EBOV) and marburg virus (MARV), arenaviridae: lassa virus (LASV) and machupo virus (MACV), herpesviridae: kaposis sarcoma-associated herpesvirus (KSHV), rhabdoviridae: vesicular stomatitis virus (VSV), orthomyxoviridae: influenza A virus, paramyxoviridae: nipah virus, and coronaviridae: SARS-CoV (PubMed:18200009, 18342597, 19179289, 19879838, 20399176, 20419159, 20686043, 20943977, 21529378, 21621240, 22520941, 26378163, 31199522). Can inhibit cell surface proteolytic activity of MMP14 causing decreased activation of MMP15 which results in inhibition of cell growth and migration (PubMed:22065321). Can stimulate signaling by LILRA4/ILT7 and consequently provide negative feedback to the production of IFN by plasmacytoid dendritic cells in response to viral infection (PubMed:19564354, 26172439). Plays a role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. Isoform 1 and isoform 2 are both effective viral restriction factors but have differing antiviral and signaling activities (PubMed:23028328, 26172439). Isoform 2 is resistant to HIV-1 Vpu-mediated degradation and restricts HIV-1 viral budding in the presence of Vpu (PubMed:23028328, 26172439). Isoform 1 acts as an activator of NF-kappa-B and this activity is inhibited by isoform 2 (PubMed:23028328). ( BST2_HUMAN,Q10589 ) 

 

 

Lisätieto 6.10.-2025:   EBOV , proteiini GP .

https://ictv.global/report/chapter/filoviridae/filoviridae/orthoebolavirus 

GeneCards tieto:   Virion adsorption to orthoebolavirus susceptible cells via cellular attachment factors; determines orthoebolavirus cell and tissue tropism; induction of virus cell membrane fusion subsequent to endolysosomal binding to NPC1; inhibits innate immune response by interfering with BST2. GP_1,2Δ triggers immune activation and increased vascular permeability 

 

 

PubMed haku:  EBOV interaction with BST2? 5 vastausta: 

 

Release of Immunomodulatory Ebola Virus Glycoprotein-Containing Microvesicles Is Suppressed by Tetherin in a Species-Specific Manner.

Nehls J, Businger R, Hoffmann M, Brinkmann C, Fehrenbacher B, Schaller M, Maurer B, Schönfeld C, Kramer D, Hailfinger S, Pöhlmann S, Schindler M. Cell Rep. 2019 Feb 12;26(7):1841-1853.e6. doi: 10.1016/j.celrep.2019.01.065. PMID: 30759394 Free article.

We characterized GP-mediated virosome formation and delineated the role of the antiviral factor tetherin (BST2, CD317) in this process. Residues in the EBOV-GP receptor-binding domain (RBD) promote GP-virosome secretion, while tetherin suppresses GP-virosomes by …

2

A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism.

González-Hernández M, Hoffmann M, Brinkmann C, Nehls J, Winkler M, Schindler M, Pöhlmann S. J Virol. 2018 Jun 13;92(13):e00403-18. doi: 10.1128/JVI.00403-18. Print 2018 Jul 1. PMID: 29669839 Free PMC article.

Moreover, alteration of the GXXXA motif increased tetherin sensitivity of a replication-competent vesicular stomatitis virus (VSV) chimera encoding EBOV-GP. Although these results await confirmation with authentic EBOV, they indicate that a GXXXA motif in the TMD of …

3

The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.

Brinkmann C, Nehlmeier I, Walendy-Gnirß K, Nehls J, González Hernández M, Hoffmann M, Qiu X, Takada A, Schindler M, Pöhlmann S. J Virol. 2016 Nov 28;90(24):11075-11086. doi: 10.1128/JVI.01563-16. Print 2016 Dec 15. PMID: 27707924 Free PMC article.

The glycoprotein of Ebola virus (EBOV GP), a member of the family Filoviridae, facilitates viral entry into target cells. In addition, EBOV GP antagonizes the antiviral activity of the host cell protein tetherin, which may otherwise restrict EBOV release from …

4

Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin.

Gustin JK, Bai Y, Moses AV, Douglas JL. J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S181-90. doi: 10.1093/infdis/jiv125. Epub 2015 Mar 27. PMID: 25821226 Free PMC article.

Coincident with this discovery was the finding that the HIV Vpu protein down-regulates BST2 from the cell surface, thereby promoting viral release. Evidence suggests that the EBOV envelope glycoprotein (GP) also counteracts BST2, although the mechanism is unc …

5

The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin.

Kühl A, Banning C, Marzi A, Votteler J, Steffen I, Bertram S, Glowacka I, Konrad A, Stürzl M, Guo JT, Schubert U, Feldmann H, Behrens G, Schindler M, Pöhlmann S. J Infect Dis. 2011 Nov;204 Suppl 3(Suppl 3):S850-60. doi: 10.1093/infdis/jir378. PMID: 21987761 Free PMC article.

The antiviral protein tetherin/BST2/CD317/HM1.24 restricts cellular egress of human immunodeficiency virus (HIV) and of particles mimicking the Ebola virus (EBOV), a hemorrhagic fever virus. ...Tetherin interacted with the GP2 subunit of EBOV-GP, which …